The Continuing Plague of Extended-Spectrum β-Lactamase Producing Enterbacterales Infections: An Update

Infect Dis Clin North Am. 2020 Dec;34(4):677-708. doi: 10.1016/j.idc.2020.06.003. Epub 2020 Sep 30.

Abstract

Antimicrobial resistance is a common iatrogenic complication of modern life and medical care. One of the most demonstrative examples is the exponential increase in the incidence of extended-spectrum β-lactamases (ESBLs) production among Enterobacteriaceae, that is, the most common human pathogens outside of the hospital setting. Infections resulting from ESBL-producing bacteria are associated with devastating outcomes, now affecting even previously healthy individuals. This poses an enormous burden and threat to public health. This article aims to narrate the evolving epidemiology of ESBL infections and highlights current challenges in terms of management and prevention of these common infections.

Keywords: Escherichia coli; Gram-negative; Klebsiella pneumoniae; MDRO; Proteus mirabilis.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Carbapenems / pharmacology
  • Carbapenems / therapeutic use*
  • Continuity of Patient Care
  • Early Diagnosis
  • Enterobacteriaceae / classification*
  • Enterobacteriaceae / drug effects
  • Enterobacteriaceae / enzymology
  • Enterobacteriaceae / isolation & purification
  • Enterobacteriaceae Infections / diagnosis*
  • Enterobacteriaceae Infections / drug therapy
  • Humans
  • Time-to-Treatment
  • beta-Lactamases / genetics*

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • beta-Lactamases